Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.34)
# 1,010
Out of 4,761 analysts
100
Total ratings
50.91%
Success rate
3.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $68.25 | +31.87% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $484.24 | -0.88% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $55.83 | -1.49% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $109.95 | -27.24% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $9.18 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $700.33 | +44.93% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $303.01 | +33.66% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $250.59 | -12.21% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $7.93 | +26.10% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $5.76 | +12.85% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $47.91 | +50.28% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $68.25
Upside: +31.87%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $484.24
Upside: -0.88%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $55.83
Upside: -1.49%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $109.95
Upside: -27.24%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $9.18
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $700.33
Upside: +44.93%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $303.01
Upside: +33.66%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $250.59
Upside: -12.21%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.93
Upside: +26.10%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.76
Upside: +12.85%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $47.91
Upside: +50.28%